The $7.14 Is The Price At Which Relay Therapeutics Inc (NASDAQ: RLAY) Deserves Consideration

During the last session, Relay Therapeutics Inc (NASDAQ:RLAY)’s traded shares were 1.89 million, with the beta value of the company hitting 1.64. At the end of the trading day, the stock’s price was $7.14, reflecting an intraday loss of -6.05% or -$0.46. The 52-week high for the RLAY share is $19.23, that puts it down -169.33 from that peak though still a striking 16.67% gain since the share price plummeted to a 52-week low of $5.95. The company’s market capitalization is $936.63M, and the average intraday trading volume over the past 10 days was 1.21 million shares, and the average trade volume was 1.10 million shares over the past three months.

Relay Therapeutics Inc (NASDAQ:RLAY) trade information

Relay Therapeutics Inc (RLAY) registered a -6.05% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -6.05% in intraday trading to $7.14, hitting a weekly high. The stock’s 5-day price performance is -5.68%, and it has moved by -29.66% in 30 days. Based on these gigs, the overall price performance for the year is -56.65%. The short interest in Relay Therapeutics Inc (NASDAQ:RLAY) is 11.81 million shares and it means that shorts have 9.96 day(s) to cover.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Relay Therapeutics Inc (RLAY) estimates and forecasts

Statistics show that Relay Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Relay Therapeutics Inc (RLAY) shares have gone down -12.29% during the last six months, with a year-to-date growth rate less than the industry average at -1.79% against 8.20. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 10.30% this quarter and then jump 9.90% in the quarter after that. In the rating firms’ projections, revenue will decrease -99.20% compared to the previous financial year.

Revenue for the current quarter is expected to be $70k as predicted by 7 analyst(s). Meanwhile, a consensus of 7 analyst(s) estimates revenue growth to $70k by the end of Jun 2024. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $226k and $750k respectively. In this case, analysts expect current quarter sales to shrink by -69.00% and then drop by -90.70% in the coming quarter.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -38.74%. While earnings are projected to return -3.44% in 2024.

RLAY Dividends

Relay Therapeutics Inc is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Relay Therapeutics Inc (NASDAQ:RLAY)’s Major holders

Relay Therapeutics Inc insiders own 3.49% of total outstanding shares while institutional holders control 99.08%, with the float percentage being 102.66%. SB Investment Advisers (UK) LTD is the largest shareholder of the company, while 262 institutions own stock in it. As of Jun 29, 2023, the company held over 27.9 million shares (or 22.85% of all shares), a total value of $350.49 million in shares.

The next largest institutional holding, with 10.53 million shares, is of Vanguard Group Inc’s that is approximately 8.62% of outstanding shares. At the market price on Jun 29, 2023, these shares were valued at $132.24 million.

Also, the Mutual Funds coming in first place with the largest holdings of Relay Therapeutics Inc (RLAY) shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. Data provided on Aug 30, 2023 indicates that SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF owns about 5.28 million shares. This amounts to just over 4.33 percent of the company’s overall shares, with a $53.99 million market value. The same data shows that the other fund manager holds slightly less at 3.64 million, or about 2.98% of the stock, which is worth about $45.67 million.